The relationship between insulin sensitivity and heart rate-corrected QT interval in patients with type 2 diabetes

Xiao-hua Yang1,2,†, Jian-bin Su1,3,†, Xiu-Lin Zhang4, Li-hua Zhao3, Feng Xu3, Xue-qin Wang3 and Xing-bo Cheng1*

Abstract

Background: Reduced insulin sensitivity not only contributes to the pathogenesis of type 2 diabetes but is also linked to multiple metabolic risk factors and cardiovascular diseases (CVD). A prolonged heart rate-corrected QT interval (QTc interval) is related to ventricular arrhythmias and CVD mortality and exhibits a high prevalence among type 2 diabetes patients. The aim of the study was to investigate the relationship between insulin sensitivity and the QTc interval in patients with type 2 diabetes.

Methods: This cross-sectional observational study recruited 2927 patients with type 2 diabetes who visited the Affiliated Haian Hospital and Second Affiliated Hospital of Nantong University. The insulin sensitivity index (Matsuda index, ISIMatsuda) derived from 75-g OGTT and other metabolic risk factors were examined in all patients. The QTc interval was estimated using a resting 12-lead electrocardiogram, and an interval longer than 440 ms was considered abnormally prolonged.

Results: The QTc interval was significantly and negatively correlated with the ISIMatsuda (r = −0.296, p < 0.001), and when the multiple linear regression analysis was adjusted for anthropometric parameters, metabolic risk factors, and current antidiabetic treatments, the QTc interval remained significantly correlated with the ISIMatsuda (β = −0.23, t = −12.63, p < 0.001). The proportion of patients with prolonged QTc interval significantly increased from 12.1% to 17.9%, 25.6% and 37.9% from the fourth to third, second and first quartile of the ISIMatsuda, respectively. After adjusting for anthropometric parameters by multiple logistic regression analysis, the corresponding odd ratios (ORs) for prolonged QTc interval of the first, second and third quartiles versus the fourth quartile of ISIMatsuda were 3.11 (95% CI 2.23–4.34), 2.09 (1.51–2.88) and 1.53 (1.09–2.14), respectively, and p for trend was <0.001.

Conclusions: Reduced insulin sensitivity is associated with an increase in the QTc interval in patients with type 2 diabetes.

Keywords: Insulin sensitivity, QTc interval, Type 2 diabetes

Background

Reduced insulin sensitivity, which contributes to the pathogenesis of type 2 diabetes, is closely linked to metabolic risk factors and cardiovascular diseases (CVD) [1]. Blunted insulin sensitivity substantially contributes to many metabolic disorders, including central obesity, hypertension, hyperglycaemia, dyslipidemia and atherosclerotic vascular disease [2]. These multiple risk factors may in turn be responsible for a two- to four-fold increase in coronary artery disease and an increase in all-cause and CVD mortality in type 2 diabetes patients compared to the rate in nondiabetic populations [3, 4].

Insulin sensitivity can be quantified with the hyperinsulinemic-euglycemic clamp technique [5]. However, the technique is laborious and is hard to be applied in large-scale clinical or epidemiologic studies. A surrogate measure of insulin sensitivity has been derived from the
oral glucose tolerance test (OGTT). The OGTT-based Matsuda index, which is a validated measure of systemic insulin sensitivity, is closely associated with the glucose disposal rate of whole-body during the hyperinsulinemic-euglycemic clamps [5]. The QT interval reflects the total time taken for ventricular myocardial depolarization (QRS complex) and repolarization (T wave). The prolonged heart rate-corrected QT interval (QTc interval) may not only impart ventricular arrhythmias but is also associated with increased all-cause and CVD-related mortality in type 2 diabetes patients [6–8]. A prolonged QTc interval has been shown to be related to various markers of reduced insulin sensitivity, such as abdominal adiposity, hyperlipidaemia, hypertension and hyperinsulinemia [9]. The prevalence of QTc interval prolongation is relatively high in type 2 diabetes patients [10, 11], possibly due to reduced insulin sensitivity. We hypothesize that reduced insulin sensitivity may play a vital role in the prolonged QTc interval in type 2 diabetes, although previous studies have implicated a weak association of insulin resistance with an increased QTc interval in a relatively small sample size of type 2 diabetes patients [12]. If the close relationship between insulin sensitivity and the QTc interval could be demonstrated, strategies targeting to improve insulin sensitivity may ameliorate the prolongation of the QTc interval and improve prognosis in type 2 diabetes patients.

The aim of this study was to explore the relationship between insulin sensitivity assessed by the Matsuda index and the QTc interval from a standard baseline 12-lead electrocardiogram (ECG) in a large Chinese population with type 2 diabetes.

Methods

Study design and participants

This cross-sectional study included 2927 patients with type 2 diabetes who were followed-up at the outpatientsof the Affiliated Haian Hospital and Second Affiliated Hospital of Nantong University from January 2011 to December 2015. The inclusion criteria were as follows: (1) diagnosis of type 2 diabetes according to the criteria of ADA in 2011 [13] and (2) current use of antidiabetic treatments for more than 3 months. The exclusion criteria were as follows: (1) type 1 diabetes, testing positive for glutamic acid decarboxylase antibody or insulin antibody; (2) type 2 diabetic patients, who presented with instability of glycemic control and high risks of hypoglycemia, and treated with basal-bolus insulin, could not tolerate the OGTT; (3) fibrillation or flutter, atrioventricular blocks, and bundle-branch blocks; (4) heart valve disease, myocardial infarction, and heart surgery; (5) use of any drugs known to affect the QT interval such as tricyclic antidepressants; (6) chronic hepatic disease and kidney disease or malignancy; (7) excessive drinking (alcohol consumption more than 40 g of ethanol daily for women or 60 g daily for men); and (8) acute complications of diabetes, such as hyperglycemic hyperosmolar state and diabetic ketoacidosis; and (9) other endocrine disorders may have effect on glycaemic metabolism, such as hypothyroidism and hyperthyroidism. And informed consents in writing were received from all participants. The study protocol was reviewed and approved by the Medical Ethics Committee of the Affiliated Haian Hospital and Second Affiliated Hospital of Nantong University.

Baseline data collection

Upon enrolment, all participants were interviewed by trained investigators to record their age, sex, medication use (antidiabetic treatments, hypertensive treatment, and statin medications), health behaviours (smoking and drinking), and medical history of coronary heart disease (CHD). The antidiabetic treatments included lifestyle intervention alone, insulin injection, insulin secretagogues, and insulin sensitizers. CHD was proven by coronary angiography. Body mass index (BMI) was calculated as weight divided by the height square for further analysis. Those with SBP ≥ 140 mmHg, with DBP ≥ 90 mmHg, or receiving antihypertensive agents were considered as hypertensive.

OGTT procedures and insulin sensitivity index

After an overnight fast, the 75-g OGTT was performed during the early morning. All antidiabetic treatments were withheld at least 24 h before the OGTT. Blood samples were collected at basal, and 30, 60, 120, and 180 min after glucose ingestion for the determinations of plasma glucose and insulin levels. Insulin sensitivity was assessed using the insulin sensitivity index (ISI) proposed by Matsuda and DeFronzo [5].

\[ \text{ISI}_{\text{Matsuda}} = \frac{10,000}{\sqrt{\text{mean}\text{blood glucose}} \times \text{mean}\text{insulin during the OGTT}} \]

QT interval from electrocardiogram (ECG)

Standard resting 12-lead ECGs (FX-7402, CardiMax, FuTian Beijing Ltd., China) was performed for all participants. The ECG from each participant was recorded on a standard paper with a waveforms-amplitude of 10 mm/mV and a travelling-rate of 25 mm/s. The QT and RR intervals from ten consecutive beats were simultaneously assessed on the ECG. And QT and RR intervals were measured in lead II by two independent experienced physicians who were blinded to the personal information of participants. The QT interval was defined as the duration...
Results

Clinical characteristics

The clinical characteristics of the total participants and four subgroups according to the ISIMatsuda quartiles are shown in Table 1, and the distribution of the QTc interval and ISIMatsuda are shown in Figs. 1, 2. The mean QTc interval among all participants was 419 ± 32 ms, and the prevalence of the prolonged QTc interval in our study was 23.4%. The QTc interval significantly increased from 408 ± 31 to 414 ± 31 ms, 423 ± 29 and 432 ± 33 ms from ISIMatsuda Q4 to Q1, and the corresponding proportion of patients with prolonged QTc interval significantly increased from 12.1% to 17.9%, 25.6%, and 37.9% from ISIMatsuda Q4 to Q1, respectively. As the ISIMatsuda quartiles decreased, the ratio of females, BMI, SBP, ratio of hypertension and statin medication, frequency of drinking and CHD, and values of TG, TC, LDLC, serum UA and HbA1c significantly increased, whereas the HDLC level decreased. Age, DBP, diabetic duration and the frequency of smoking did not show differences among the ISIMatsuda quartiles. Comparisons of hypoglycaemic treatments showed that the frequency of insulin treatment increased as the ISIMatsuda quartiles decreased, whereas secretagogues and sensitizers use were comparable among the ISIMatsuda quartiles. The tendency of lifestyle intervention alone was increased when the ISIMatsuda quartiles increased, but the difference was not significant (p for trend = 0.067).

Multiple linear stepwise regression analysis with QTc interval as the dependent variable

The QTc interval was significantly correlated with the ISIMatsuda in the univariate analysis, and a multiple linear stepwise regression analysis was further performed to assess the associations of the ISIMatsuda and other clinical risk factors, as independent variables, with the QTc interval as the dependent variable for the participants. The independent factors included age, female, BMI, SDP, DBP, diabetic duration, antidiabetic treatments, statins medication, hypertension, drinking, smoking, CHD, TG, TC, HDLC, LDLC, serum UA, and HbA1c. After adjusting for the metabolic risk factors in the multiple linear regression analysis, ISIMatsuda, female gender, age, hypertension, insulin treatments and serum UA (β = −0.23, 0.22, 0.13, 0.078, 0.062 and 0.059, respectively, p < 0.005,
The prevalence of prolonged QTc interval was considerably high in this large Chinese population with type 2 diabetes, and the incidence was 23.4%; second, a reduced ISI\textsubscript{Matsuda} was a major independent contributor to the increase in QTc interval (Table 2), and the ISI\textsubscript{Matsuda} was the main independent contributor (standardized coefficient $\beta = -0.23$, $t = -12.63$, $p < 0.001$, partial $R^2 = 8.5\%$).

**Table 1** Clinical characteristics of the participants according to ISI\textsubscript{Matsuda} quartiles

| Variables | Total | Q1 | Q2 | Q3 | Q4 | $p$ for trend |
|-----------|-------|----|----|----|----|-------------|
| ISI\textsubscript{Matsuda} | 99.4 (65.9–151.8) | 48.2 (36.9–57.9) | 82.0 (73.6–89.8) | 120.7 (109.5–135.4) | 214.8 (175.0–289.8) | <0.001 |
| log ISI\textsubscript{Matsuda} | 4.61 ± 0.67 | 3.78 ± 0.36 | 4.40 ± 0.12 | 4.80 ± 0.16 | 5.46 ± 0.37 | <0.001 |
| n | 2927 | 733 | 727 | 730 | 737 | – |
| Age (years) | 56 ± 14 | 57 ± 14 | 56 ± 14 | 56 ± 13 | 55 ± 13 | 0.280 |
| Female, n (%) | 1394 (47.6) | 428 (58.4) | 368 (50.6) | 298 (40.8) | 300 (40.7) | <0.001 |
| BMI (kg/m\textsuperscript{2}) | 25.0 ± 0.67 | 26.3 ± 0.41 | 25.5 ± 0.39 | 24.5 ± 3.6 | 23.6 ± 3.3 | <0.001 |
| SBP (mmHg) | 135 ± 17 | 137 ± 17 | 136 ± 18 | 134 ± 17 | 132 ± 18 | <0.001 |
| DBP (mmHg) | 80 ± 11 | 80 ± 10 | 80 ± 11 | 80 ± 10 | 79 ± 11 | 0.073 |
| Diabetic duration (years) | 3.0 (0.3–9.0) | 4.0 (0.3–10.0) | 3.0 (0.3–8.0) | 3.0 (0.3–8.0) | 3.0 (0.3–9.0) | 0.209 |
| Antidiabetic treatment | | | | | | |
| Lifestyle intervention alone, n (%) | 313 (10.7) | 69 (9.4) | 71 (9.8) | 79 (10.8) | 94 (12.8) | 0.067 |
| Insulin treatments, n (%) | 871 (29.8) | 259 (35.3) | 217 (29.8) | 198 (27.1) | 197 (26.7) | 0.031 |
| Statins medication, n (%) | 1168 (39.9) | 255 (34.8) | 296 (40.7) | 264 (36.2) | 216 (26.2) | <0.001 |
| Smoking, n (%) | 892 (30.5) | 231 (31.5) | 232 (31.9) | 215 (29.5) | 215 (29.0) | 0.193 |
| Drinking, n (%) | 476 (16.3) | 159 (21.7) | 131 (18.0) | 119 (16.3) | 67 (9.1) | <0.001 |
| CHD, n (%) | 262 (9.0) | 82 (11.2) | 74 (10.2) | 49 (6.7) | 80 (11.4) | <0.001 |
| TG (mmol/L) | 1.61 (1.02–2.59) | 2.06 (1.33–3.20) | 1.76 (1.15–2.74) | 1.56 (1.00–2.47) | 1.15 (0.77–1.86) | <0.001 |
| TC (mmol/L) | 4.73 ± 1.25 | 4.82 ± 1.43 | 4.81 ± 1.21 | 4.75 ± 1.19 | 4.53 ± 1.14 | <0.001 |
| HDLC (mmol/L) | 1.07 ± 0.29 | 1.03 ± 0.26 | 1.06 ± 0.26 | 1.07 ± 0.30 | 1.13 ± 0.31 | <0.001 |
| LDLC (mmol/L) | 2.51 ± 0.82 | 2.55 ± 0.81 | 2.54 ± 0.85 | 2.48 ± 0.81 | 2.45 ± 0.80 | 0.021 |
| Serum UA (μmol/L) | 286 ± 105 | 305 ± 104 | 285 ± 101 | 285 ± 102 | 270 ± 108 | <0.001 |
| HbA1c (%) | 8.29 ± 0.21 | 8.51 ± 1.32 | 8.36 ± 1.22 | 8.23 ± 1.18 | 8.08 ± 1.14 | <0.001 |
| QTc (ms) | 419 ± 32 | 432 ± 33 | 423 ± 29 | 414 ± 31 | 408 ± 31 | <0.001 |
| Prolonged QTc, n (%) | 684 (23.4) | 278 (37.9) | 186 (25.6) | 131 (17.9) | 89 (12.1) | <0.001 |

Normally distributed values in the table are given as the mean ± SD, non-normally distributed values are given as the median (25 and 75% interquartiles), and categorical variables are given as frequency (percentage).

ISI\textsubscript{Matsuda} Insulin sensitivity index of Matsuda, QTc heart rate-corrected QT, BMI body mass index, SBP/DBP systolic/diastolic blood pressure, TC total cholesterol, TG triglyceride, HDLC high density lipoprotein cholesterol, LDLC low density lipoprotein cholesterol, Serum UA serum uric acid, HbA1c glycosylated hemoglobin A1c, CHD coronary heart disease.

$p$ values for continuous variables and categorical variables were determined by ANOVA and the Chi square test, respectively.

Odd ratios (ORs) of prolonged QTc interval according to quartiles of ISI\textsubscript{Matsuda}

Table 3 also shows the ORs of the prolonged QTc interval according to the ISI\textsubscript{Matsuda} quartiles. Compared with participants in Q4 of ISI\textsubscript{Matsuda} the ORs of prolonged QTc interval for Q1, Q2 and Q3 of ISI\textsubscript{Matsuda} were 4.45 (95% CI 3.41–5.81), 2.50 (1.89–3.30) and 1.59 (1.19–2.13), respectively. After adjustment in the multiple logistic regression, the corresponding ORs of the prolonged QTc interval for Q1, Q2 and Q3 of ISI\textsubscript{Matsuda} versus Q4 were 3.11 (2.23–4.34), 2.09 (1.51–2.88) and 1.53 (1.09–2.14), respectively.

**Discussion**

In the present study, we investigated the association of insulin sensitivity, assessed by the ISI\textsubscript{Matsuda}, with the QTc interval in a large Chinese population with type 2 diabetes. The strengths of our study were follows: first, the prevalence of prolonged QTc interval (>440 ms) was considerably high in this large Chinese population with type 2 diabetes, and the incidence was 23.4%; second, a reduced ISI\textsubscript{Matsuda} was a major independent risk factor for an increase in QTc interval in type 2 diabetes patients after adjusting for other metabolic risk factors in the multiple regression analysis; third, compared to patients from the fourth ISI\textsubscript{Matsuda} quartile, patients from the third quartile had a significantly higher risk of prolonged QTc interval (OR = 3.06, 95% CI 2.33–4.06).
quartile, those in the third, second and first ISI\textsubscript{Matsuda} quartiles were associated with an increased risk of a prolonged QTc interval with multiple-adjusted ORs of 1.53 (1.09–2.14), 2.09 (1.51–2.88) and 3.11 (2.23–4.34), respectively.

The metabolic risks of an increased QTc interval in type 2 diabetes patients

The prevalence of the QTc interval prolongation is considerably high in patients with type 2 diabetes, and many diabetes-related risks may contribute to the increase in the QTc interval. An increased QTc interval may be related to cigarette smoking [15], obesity [16], non-alcoholic fatty liver disease [17], hypertension [18], UA [19], dyslipidemia [20], hyperinsulinemia [21], glycaemic status [22], coronary artery disease [10], carotid intima media thickness [23], diabetic neuropathy [24, 25] and diabetic retinopathy [14]. Meanwhile, reduced insulin sensitivity is the pathophysiologic basis of type 2 diabetes and may underlie above cited risks factors. These risks factors that are associated with decreased insulin sensitivity are the same as those favoring the prolongation of the corrected QT interval. In the present study, insulin sensitivity assessed by the ISI\textsubscript{Matsuda}, insulin treatment, hypertension and serum UA, was significantly associated with an increase in the QTc interval apart from non-modifiable risk factors including age and female. The associations of hypertension, serum UA, age and female with an increased QTc interval were consistent with previous studies. Gastaldelli et al. [26] demonstrated that physiological hyperinsulinemia induced by the euglycaemic insulin clamp acutely prolonged ventricular repolarization as assessed by the QTc in healthy volunteers. Our study revealed that insulin treatment was an independent risk for an increase in the QTc interval. Insulin may prolong the QTc interval in both healthy subjects and diabetic patients. With regard to the relationship between insulin sensitivity and the QTc interval, Shin et al. [27] showed that insulin resistance was an important risk for the prolongation of the QTc interval in normoglycaemic female subjects, and Festa et al. [12] found a weak association of the increased QTc interval with blunted insulin sensitivity, as determined by an intravenous glucose tolerance test in established diabetic patients ($r = -0.15$). Our study revealed that reduced insulin sensitivity assessed by the ISI\textsubscript{Matsuda} was a major independent contributor to the increase in the QTc interval and accounted for 8.5% of its variation. Strategies targeting to improve insulin sensitivity may provide therapeutic methods to ameliorate the prolongation of the QTc interval and its associated prognosis in type 2 diabetes patients.
Reduced insulin sensitivity, related risk factors and cardiovascular complications of type 2 diabetes

Reduced insulin sensitivity is the pathophysiologic basis of type 2 diabetes and may underlie a host of metabolic and cardiovascular disorders including glycaemic abnormality, dyslipidemia, hypertension and abdominal adiposity, which comprise the basis of the metabolic syndrome [2]. Each component of metabolic syndrome, which is characterized by reduced insulin sensitivity, is a significant risk factor for CVD. Metabolic syndrome can promote both atherosclerosis and atherosclerotic plaque formation, and the mechanisms possibly involve interaction of the components of metabolic syndrome that promote these processes [28]. Several prospective studies have demonstrated an association between reduced insulin sensitivity and severity of cardiovascular diseases in type 2 diabetes.

Table 2  Multiple linear regression analysis to explore in dependent risks of QTc interval

| Variables          | B    | SE  | β    | t    | p     | R²   |
|--------------------|------|-----|------|------|-------|------|
| log ISIMatsuda     | -11.22 | 0.89 | -0.23 | -12.63 | <0.001 | 8.5  |
| Female             | 16.11  | 1.21 | 0.22  | 12.27 | <0.001 | 6.1  |
| Age                | 0.32   | 0.045 | 0.13  | 7.05  | <0.001 | 2.5  |
| Hypertension       | 5.10   | 1.26  | 0.078 | 4.05  | <0.001 | 0.7  |
| Insulin treatments | 4.23   | 1.23  | 0.062 | 3.44  | 0.001  | 0.4  |
| Serum UA           | 0.018  | 0.006 | 0.059 | 3.056 | 0.002  | 0.3  |

β regression coefficient, SE standard error, β standardized coefficient
patients [2]. The Verona Diabetes Complications Study by Bonora et al. [29] showed insulin resistance that derived from HOMA was a major predictor for CVD in population with type 2 diabetes. In type 2 diabetes patients, the presence of metabolic syndrome was associated with a nearly fivefold increase in risk of cardiovascular diseases [30]. Our study documented that reduced insulin sensitivity as assessed by the ISIMatsuda was significantly associated with an increase in the QTc interval, which represented the ventricular myocardial membrane electrical destabilization, in type 2 diabetes patients.

The possible mechanisms linking reduced insulin sensitivity and the QTc interval

The QTc interval reflects the total time taken for ventricular myocardial depolarization and repolarization, and metabolic, morphological, functional and structural abnormalities of the myocardium may induce ventricular myocardial membrane electrical destabilization and a subsequent increase in the QT interval. In an animal study, Lin et al. [31] observed that obese, insulin-resistant, 16 to 17-week-old rats developed cardiac hypertrophy, exhibited defective inactivation of current, and presented altered electrophysiology characterized by a prolongation of QTc interval. This study suggests that defective calcium inactivation can cause prolongation of the QT interval in patients presented with insulin resistance. Type 2 diabetes is associated with a high prevalence of left ventricular hypertrophy [32], and left ventricular mass is a strong determinant of the QT interval in these patients [9]. Insulin resistance may be important in the development of left ventricular diastolic dysfunction and structure in patients with type 2 diabetes mellitus [33–35]. Insulin resistance and associated hyperinsulinemia in type 2 diabetes can promote the development of a specific form of cardiomyopathy, which is also termed diabetic cardiomyopathy, manifested by left ventricular hypertrophy and diastolic dysfunction [36]. The myocardial triglyceride content is increased in type 2 diabetes patients with insulin resistance [37] and could contribute to concentric remodelling and contractile dysfunction of the left ventricle [38].

Limitations

It should be noted that our study had several limitations. First, it was a cross-sectional observational study that cannot definitively determine the causality of the association between reduced insulin sensitivity and an increase in the QTc interval. In addition, prospective longitudinal studies are needed to evaluate the cause-effect relationship. Second, this cross-sectional study was performed in a Chinese population, and our findings may lack generalizability to other populations. Third, insulin sensitivity should be assessed by the euglycaemic insulin clamp technique as the gold standard, but this technique was difficult to apply in large epidemiological studies. Insulin sensitivity assessed by the Matsuda index was easily applied in the present large-scale clinical study. Fourth, evaluating insulin sensitivity by ISIMatsuda required endogenous insulin secretion, so this method would not be applicable to diabetic patients with very deficient insulin in response to exogenous glucose. Fifth, although all antidiabetic treatments were withheld at least 24 h before the OGTT, using insulin and insulin sensitizer in diabetic patients may affect the results on OGTT-based insulin sensitivity index. Sixth, we did not analyzed the association of QTc interval with diabetic neuropathy, which may influence the value of QTc interval in the previous studies [24, 25].

Conclusions

In summary, reduced insulin sensitivity assessed by the Matsuda index is associated with an increase in the QTc interval on standard baseline 12-lead ECGs in type 2 diabetes patients.

Table 3 ORs for prolonged QTc interval according to ISIMatsuda quartiles (95% CI)

| ISIMatsuda quartiles | Q1                | Q2                | Q3                | Q4                | P for trend |
|----------------------|-------------------|-------------------|-------------------|-------------------|------------|
| n                    | 733               | 727               | 730               | 737               |            |
| Model 1              | 4.45 (3.41–5.81)  | 2.50 (1.89–3.30)  | 1.59 (1.19–2.13)  | 1-Reference       | <0.001     |
| Model 2              | 4.29 (3.25–5.65)  | 2.46 (1.85–3.26)  | 1.59 (1.18–2.14)  | 1-Reference       | <0.001     |
| Model 3              | 3.58 (2.62–4.88)  | 2.12 (1.56–2.89)  | 1.55 (1.13–2.14)  | 1-Reference       | <0.001     |
| Model 4              | 3.12 (2.24–4.34)  | 2.08 (1.50–2.87)  | 1.50 (1.07–2.11)  | 1-Reference       | <0.001     |
| Model 5              | 3.11 (2.23–4.34)  | 2.09 (1.51–2.88)  | 1.53 (1.09–2.14)  | 1-Reference       | <0.001     |

Model 1 unadjusted model, Model 2 adjusted for age and diabetic duration, Model 3 additionally adjusted for female, BMI, SBP/DBP, drinking, smoking, statins, medication, hypertension and history of CHD, Model 4 additionally adjusted for HbA1c, serum UA, TG, TC, HDLC, and LDLC, Model 5 additionally adjusted for lifestyle intervention alone, insulin treatments, insulin secretagogues and insulin sensitizers.

Abbreviations

QTc: heart rate-corrected QT; ISIMatsuda: insulin sensitivity index of Matsuda; BMI: body mass index; SBP/DBP: systolic/diastolic blood pressure; TC: total cholesterol; TG: triglyceride; HDLC: high density lipoprotein cholesterol; LDLC: low density lipoprotein cholesterol; UA: uric acid; HbA1c: glycosylated hemoglobin.
A1c, OGTT: oral glucose tolerance test; CVD: cardiovascular diseases; CHD: coronary heart disease.

Authors’ contributions
XY and JS participated in the design of the study, data collection, analysis of the data, drafting of the manuscript. XC and XW conceived of the study, participated in its design and revised the manuscript. XZ, LZ and FX participated in data collection. All authors read and approved the final manuscript.

Author details
1 Department of Endocrinology, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215006, China. 2 Department of Endocrinology, The Affiliated Haian Hospital of Nantong University, No. 17 Middle Zhongba Road, Haian 226600, China. 3 Department of Endocrinology, The Second Affiliated Hospital of Nantong University, No. 6 North Hai-er-xiang Road, Nantong 226001, China. 4 Department of Clinical Laboratory, The Second Affiliated Hospital of Nantong University, No. 6 North Hai-er-xiang Road, Nantong 226001, China.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The data of the current is made available to all interested researchers upon reasonable request. Requests for access to the data should be made to principal investigators of the study, Xiao-hua Yang (e-mail:80298251@qq.com) and Xing-bo Chen (e-mail: xingbo1107@sohu.com).

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by the institutional review board of the Affiliated Haian Hospital and Second Affiliated Hospital of Nantong University, with written informed consent being obtained from all participants.

Funding
The study was funded by the Scientific Research Program of Nantong (MS22015065), the Scientific Research Program of Health and Planning Commission of Jiangsu (H201553) and the Scientific and Educational Program for Health Care Prosperity of Jiangsu (Young Medical Talents Project: QNRC2016408).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 3 May 2017 Accepted: 4 September 2017
Published online: 11 September 2017

References
1. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med. 1997;103(2):152–62.

2. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53(7):1270–87.

3. Stolar MW, Chilton RJ. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther. 2003;25(Supp B):84–31.

4. Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res. 2016;118(11):1808–29.

5. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–70.

6. Cardoso CR, Salles GF, Deccache W. Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. J Diabetes Complications. 2003;17(4):169–78.

7. Stettler C, Beauth A, Allemand S, Zwahlen M, Zanchin L, Diem P. QT interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up. Diabetologia. 2007;50(1):86–94.

8. Cox AJ, Azeem A, Yeboah J, Soliman EZ, Aggarwal SR, Bertoni AG, Carr JJ, Freedman BI, Harrington DM, Bowden DW. Heart rate-corrected QT interval is an independent predictor of all-cause and cardiovascular mortality in individuals with type 2 diabetes: the Diabetes Heart Study. Diabetes Care. 2014;37(5):1454–61.

9. Salles GF, Cardoso CR, Deccache W. Multivariate associates of QT interval parameters in diabetic patients with arterial hypertension: importance of left ventricular mass and geometric patterns. J Hypertens. 2003;17(8):561–7.

10. Vaglio M, Bruno G, Borra M, Macchia G, Bargero G, De'Errico N, Pagano GF, Cava-Perin P. Prevalence of increased QT interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease: a population-based cohort. J Intern Med. 2002;251(4):317–24.

11. Ninkovic VM, Ninkovic SM, Miloradovic V, Stanojevic D, Babic M, Giga V, Dobric M, Trenell MI, Lalic N, Seferovic PM, et al. Prevalence and factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes. Acta Diabetol. 2016;53(5):737–44.

12. Festa A, D’Agostino R Jr, Rautaharju P, Mykkkanen L, Haffner SM. Relation of systemic blood pressure, left ventricular mass, insulin sensitivity, and coronary artery disease to QT interval duration in nondiabetic and type 2 diabetic subjects. Am J Cardiol. 2000;86(10):1117–22.

13. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(Suppl 1):S6–9.

14. Subbalakshmi NK, Adhikari PM, Sathyarnayana Rao KN, Jeganathan PS. Influencing factors of QT among the clinical characteristics in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2010;88(3):265–72.

15. Thomakos P, Liatis S, Kalopita S, Vlahodimitris I, Stathi C, Katsilambros N, Tendolouris N, Makrilakis K. Cigarette smoking is associated with prolongation of the QTc interval duration in patients with type 2 diabetes mellitus. Int J Endocrinol. 2013;2013:329189.

16. Omran J, Firnana B, Koebert B, Bostick B, Alpert MA. Effect of obesity and weight loss on ventricular repolarization: a systematic review and meta-analysis. Obes Rev. 2016;17(6):520–30.

17. Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Pichiri I, Mantovani A, Zoppini G, Bonora E, Barbieri E, et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiov Dis. 2014;24(6):663–9.

18. Cardoso C, Salles G, Bloch K, Deccache W, Siqueira-Filho AG. Clinical determinants of increased QT dispersion in patients with diabetes mellitus. Int J Cardiol. 2001;79(2):253–62.

19. Guo X, Li Z, Liu Y, Yu S, Yang H, Zheng L, Zhang Y, Sun Y. Sex-specific association between serum uric acid and prolonged corrected QT interval: result from a general rural Chinese population. Medicine (Baltimore). 2016;95(50):e5568.

20. Iacobelli G, Curione M, Di Bona S, Ribaudo MC, Zappaterreno A, Veccoli E, Di Mario U, Leonetti F. Hypertension is associated with corrected QT prolongation and mortality in acutely ill patients. J Cardiovasc Nurs. 2014;29(3):264–70.

21. Strohrer B, Pichler M, Ighedbor S, Paulweber B. Relationship of QT interval duration with carotid intima-media thickness in a clinically healthy population undergoing cardiovascular risk screening. J Intern Med. 2005;257(3):328–46.

22. Fiorentini A, Perciaccante A, Valente R, Paris A, Serra P, Tubani L. The correlation among QTc interval, hyperglycaemia and the impaired autonomic function. Auton Neurosci. 2010;154(1–2):94–8.

23. Santini V, Campanerillo G, Giorgi F, Bracaglia D, Baroni A, Cicconetti E, Yeni C, Gambardella S, Frontoni S. QTc and autonomic neuropathy in diabetes: effects of acute hyperglycaemia and n-3 PUFAs. Nutr Metab Cardiovasc Dis. 2007;17(10):712–8.
26. Gastaldelli A, Emdin M, Conforti F, Camasra S, Ferrannini E. Insulin prolongs the QTc interval in humans. Am J Physiol Regul Integr Comp Physiol. 2000;279(6):R2022–5.
27. Shin HS, Lee WY, Kim SW, Jung CH, Rhee EJ, Kim BJ, Sung KC, Kim BS, Kang JH, Lee MH, et al. Sex difference in the relationship between insulin resistance and corrected QT interval in non-diabetic subjects. Circ J. 2005;69(4):409–13.
28. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14(5):575–85.
29. Bonora E, Formentini G, Calcatera F, Lombardi S, Marinì F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002;25(7):1135–41.
30. Bonora E, Targher G, Formentini G, Calcutta F, Lombardi S, Marinì F, Zenari L, Saggiani F, Poli M, Perbellini S, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona diabetes complications study. Diabet Med. 2004;21(1):52–8.
31. Lin YC, Huang J, Kan H, Castranova V, Frisbee JC, Yu HG. Defective calcium inactivation causes long QT in obese insulin-resistant rat. Am J Physiol Heart Circ Physiol. 2012;302(4):H1013–22.
32. Davson A, Morris AD, Struthers AD. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia. 2005;48(10):1971–9.
33. Hwang YC, Jee JH, Kang M, Rhee EJ, Sung J, Lee MK. Metabolic syndrome and insulin resistance are associated with abnormal left ventricular diastolic function and structure independent of blood pressure and fasting plasma glucose level. Int J Cardiol. 2012;159(2):107–11.
34. Inoue T, Maeda Y, Sonoda N, Sasaki S, Kabemura T, Kobayashi K, Inoguchi T. Hyperinsulinemia and sulfonylurea use are independently associated with left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus with suboptimal blood glucose control. BMJ Open Diabetes Res Care. 2016;4(1):e000223.
35. Bajraktari G, Koliaris MS, Ademaj F, Rexhepaj N, Qirko S, Ndrepepa G, Elezi S. Relationship between insulin resistance and left ventricular diastolic dysfunction in patients with impaired glucose tolerance and type 2 diabetes. Int J Cardiol. 2006;110(2):206–11.
36. Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12(3):144–53.
37. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A, Lamb HJ. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52(22):1793–9.
38. Levelt E, Mahmod M, Piechnik SK, Arita R, Francis JM, Rodgers CT, Clarke WT, Sabharwal N, Schneider J, Karamitsos TD, et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes. 2016;65(1):44–52.